Immunic up 26% after hours on encouraging IMU-838 data [Seeking Alpha]
Immunic, Inc. (IMUX)
Company Research
Source: Seeking Alpha
Immunic up 26% after hours on encouraging IMU-838 data Thinly traded micro cap Immunic (NASDAQ: IMUX 26% interim analysis CALDOSE-1 The data showed activity at the lowest dose (10 mg) and tolerability at the highest dose (45 mg). The trial will continue with all three dosing arms (30 mg is the other). The expansion of the potentially effective dose range will increase the target enrollment to ~240 from 195, expected to be completed in H2 2020. Topline data should be available in Q1 2021. The company says IMU-838
Show less
Read more
Impact Snapshot
Event Time:
IMUX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMUX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMUX alerts
High impacting Immunic, Inc. news events
Weekly update
A roundup of the hottest topics
IMUX
News
- Insider Buys Additional US$100k In Immunic Stock [Yahoo! Finance]Yahoo! Finance
- 75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & HepatologyPR Newswire
- Immunic, Inc. (NASDAQ: IMUX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Immunic to Present at the November 21st Virtual Investor Summit Microcap EventAccesswire
IMUX
Earnings
- 11/7/24 - Miss
IMUX
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- IMUX's page on the SEC website